

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Nanjing Leads Biolabs Co., Ltd.**  
**南京维立志博生物科技股份有限公司**

*(A joint stock company established in the People's Republic of China with limited liability)*

**(Stock Code: 9887)**

**VOLUNTARY ANNOUNCEMENT**  
**FURTHER ANNOUNCEMENT ON RESEARCH ABSTRACTS ACCEPTED**  
**FOR PRESENTATION AT THE 67TH ASH ANNUAL MEETING**

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

Reference is made to the announcement of the Company dated October 9, 2025, in relation to the acceptance of five research abstracts by the American Society of Hematology (“**ASH**”) for presentation at its 67th Annual Meeting. The Company is pleased to provide further details regarding its innovative drug candidates LBL-034 and LBL-076, for which multiple research abstracts have been accepted by the 67th ASH Annual Meeting.

Among these, one LBL-034 clinical study has been selected as the first oral presentation on the opening day, featuring the latest efficacy and safety data of LBL-034 in patients with relapsed/refractory multiple myeloma. Details are as follows:

**LBL-034 Oral Presentation**

- **Title:** *A first-in-human, phase I/II, open-label, multicenter, dose-escalation and expansion study of LBL-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma*
- **Publication Number:** 91
- **Date & Time:** December 6, 2025 | 9:30-9:45 AM EST
- **Location:** OCCC – West Hall D2
- **Session:** First oral presentation of the first session on the opening day

- **Overview:** The Phase I/II trial (NCT06049290), led by Professor Jin Lu of Peking University People's Hospital, is being conducted across 17 hospitals in China. LBL-034 demonstrated favorable safety and promising anti-tumor activity in patients with relapsed/refractory multiple myeloma (RRMM), including those with high-risk, refractory disease, particularly at doses of 800-1200 µg/kg. Updated efficacy and safety results will be presented as the opening presentation in this highly anticipated oral session on the first day of the 2025 ASH Annual Meeting.

#### **LBL-034 Poster Presentation 1**

- **Title:** *Pharmacokinetics, pharmacodynamics, and biomarkers of LBL-034, a GPRC5D-targeted T-cell engager, in a first-in-human phase I/II study in relapsed/refractory multiple myeloma*
- **Publication Number:** 4070
- **Date & Time:** December 7, 2025 | 6:00-8:00 PM EST
- **Location:** OCCC – West Halls B3-B4

#### **LBL-034 Poster Presentation 2**

- **Title:** *Proof of concept and mechanistic evaluation of LBL-034, a potent GPRC5D-targeting T-cell engager with an affinity-optimized, sterically engineered anti-CD3 arm, in a multiple myeloma xenograft mouse model*
- **Publication Number:** 2155
- **Date & Time:** December 6, 2025 | 5:30-7:30 PM EST
- **Location:** OCCC – West Halls B3-B4

#### **LBL-034 Online Publication**

- **Title:** *Population pharmacokinetics (popPK) and exposure – response (ER) analyses of LBL-034, a potent GPRC5D T-cell engager, in patients with relapsed/refractory multiple myeloma*
- **Publication Number:** 6824

## **LBL-076 Poster Presentation**

- **Title:** *LBL-076, a first-in-class GPRC5D×CD38×CD3 trispecific T-cell engager (TCE) for the treatment of relapsed/refractory multiple myeloma*
- **Publication Number:** 3302
- **Date & Time:** December 7, 2025 | 6:00-8:00 PM EST
- **Location:** OCCC – West Halls B3-B4

The Company has consistently showcased its innovative drug research and development on international platforms such as ASH and American Society of Clinical Oncology (ASCO). The inclusion of multiple research results in the 67th ASH Annual Meeting reflects strong recognition from the international academic community of the Company's scientific and innovative capabilities.

## **ABOUT LBL-034**

LBL-034 is a bispecific T-cell engager (TCE) that targets both GPRC5D and CD3, developed using the Company's proprietary LeadsBody® platform. Designed with a 2:1 binding format – two high-affinity Fabs targeting GPRC5D and one scFv targeting CD3 – LBL-034 effectively redirects and activates T cells to eliminate GPRC5D-positive cancer cells. This configuration enhances GPRC5D binding affinity and anti-tumor potency while minimizing immune exhaustion and reducing potential off-target effects on healthy tissues.

In preclinical and clinical studies, LBL-034 has demonstrated strong efficacy signals, comparable to or exceeding those of leading competitors. The molecule is currently being evaluated in a Phase I/II clinical trial for relapsed or refractory multiple myeloma (RRMM) in China. According to Frost & Sullivan, as of November 2024, LBL-034 is the second most clinically advanced GPRC5D-targeted CD3 T-cell engager globally, second only to Johnson & Johnson, and is the most advanced in China. In October 2024, LBL-034 received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of multiple myeloma.

## ABOUT LBL-076

LBL-076 is a potential first-in-class trispecific T-cell engager (TCE) targeting CD38 × GPRC5D × CD3, also developed using the Company's LeadsBody® platform. This innovative molecule simultaneously binds to GPRC5D and CD38, two validated multiple myeloma (MM) targets, while conditionally activating T cells.

LBL-076 demonstrates potent T cell – dependent cellular cytotoxicity (TDCC) against myeloma cells expressing various levels of GPRC5D and CD38, accompanied by efficient T-cell activation and mild cytokine release. Structural optimization further reduces potential cytotoxicity against CD38-expressing immune cells. In multiple multiple myeloma xenograft mouse models with heterogeneous antigen expression, LBL-076 has shown robust and durable anti-tumor activity, supporting its potential as a next-generation therapy for patients with relapsed or refractory MM.

Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board  
**Nanjing Leads Biolabs Co., Ltd.**  
南京维立志博生物科技股份有限公司  
**Dr. KANG XIAOQIANG**  
*Chairman, Executive Director and  
Chief Executive Officer*

Nanjing, PRC, November 4, 2025

*As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Ni Jia as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.*